us regulator to rule on pain drug us food and drug regulators will decide on friday whether to recommend the sale of painkillers that have been linked to a high risk of heart attack and stroke. putting vioxx back on the shelves is likely to boost profits at merck and make easier any legal battles with people who claim to have been injured by the drug analysts said. merck s head of research peter kim said that it withdrew vioxx based on the information that was available to us at the time knowing there were alternative therapies . alarm bells were rung by a research note called approve which showed that the risk of heart attack and stroke doubled in patients who had been taking the drug for at least 18 months. given this new information its is not clear that the cardiovascular risk observed in approve makes vioxx unique in the class of similar drugs marketed in the us mr kim explained.